Stryker Corporation (SYK)
Health Care · Medical devices and equipment · NYSE
A diversified global MedTech leader providing surgical instruments, robotics, and advanced clinical technologies to enhance patient recovery and healthcare outcomes.
What Stryker Corporation does
Stryker is a global medical technology company that provides innovative products and services in MedSurg, Neurotechnology, and Orthopaedics. Its portfolio includes surgical equipment, endoscopic systems, patient handling and emergency medical equipment, and robotic-arm assisted surgery technology used in joint replacements. The company serves healthcare facilities and physicians to improve patient outcomes through advanced surgical and clinical solutions.
Themes: medical robotics, surgical technology, digital health and virtual care, orthopaedic implants, hospital infrastructure, neurotechnology
Fundamentals
- Price$276.97 as of 2026-10-08 close
- Market cap$106.2B as of 2026-06-30 (share count; price 2026-10-08)
- 1-year return-26.2% 2025-10-08 close $375.29 → 2026-10-08 close $276.97
- P/E28.70 as of 2026-10-08
- Net margin+12.9% FY2025, SEC XBRL
- Gross margin+64.0% FY2025, SEC XBRL
- ROE+14.5% FY2025, SEC XBRL
- Debt / equity0.62 as of 2026-09-02
- Revenue growth (YoY)+8.5% as of 2026-09-02
- Revenue CAGR (3y)+10.8% SEC XBRL
- Beta0.56 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.3%; 8-year non-decreasing per-share dividend streak (SEC XBRL).
How SYK compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
SYK is not currently in any published Top 10 list. Its scores are below.
Top 10 score
48.0 #849 of 1,379 scored · #103 of 151 in Health Care
Profitability 66th (operating margin 19.5%, return on equity 14.5%) and financial health 59th (free cash flow margin 17.1%, debt to equity 0.6); weakest is trend (18th, a "death cross" — its 50-day average is below its 200-day).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, SYK's dividend was covered by reported results (earnings payout 40%, free-cash-flow payout 30%). This describes past coverage, not a forecast.
- Earnings payout40% dividends / net income
- Free-cash-flow payout30% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Stryker Corporation looks technically
Stryker Corporation (SYK) is trading 15.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 244 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 3.7% above its 52-week low (its lowest price of the past year). Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 15.9% below its 200-day average, the long-term trend line — a long-term downtrend | -15.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $306.21 | $306.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $329.37 | $329.37 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 268.69. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 244 trading days ago — a "death cross", a bearish long-term signal | 244 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control | 25.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($268.69 to $286.09) — its "stochastic" reading is 48 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 47.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 9 trading days ago (its momentum flipped positive) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $392.55 | $392.55 |
|---|---|---|
| From the 52-week high | it is 29.4% below its 52-week high (its highest price of the past year) | -29.4% |
| Above the 52-week low | it is 3.7% above its 52-week low (its lowest price of the past year) | +3.7% |
| Below the 52-week high | it is 29.4% below its highest point of the past year | 29.4% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $406.19 (set on 2025-01-28) | $406.19 |
| Given back of the 52-week move | over the past year its closes ranged ($269.75 to $388.35), and it has recovered only a small part of its fall from last year’s high — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $343.04 to $346.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.1% |
| From the all-time high | it is 31.8% below its all-time high | -31.8% |
| Nearest price level | it is trading 3.3% above a support level at $267.85 — a price it turned at twice since 2026-09-11, most recently on 2026-09-25. Since 2024-10-08 it has 1 such level below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.3% |
| All-time low | its lowest closing price on record is $5.53 (set on 1996-08-19) | $5.53 |
| Above the all-time low | it is 4907.4% above its all-time low | +4,907% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $7.89 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $7.89 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $268.91 and $284.83 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $268.91 – $276.87 – $284.83 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 6.6 daily ranges below its 200-day average price (15.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.03× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.5% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 2.1% below the previous close 2 sessions ago and has not traded back through the level it left behind at 285.22 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 2.5% gap up opened on 2026-09-14 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 14 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.8 percentage points (the stock gained 0.2% while the market gained 1.0%) | -0.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.1 percentage points (the stock lost 15.3% while the market gained 3.8%) | -19.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 34.1 percentage points (the stock lost 16.7% while the market gained 17.5%) | -34.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 41.2 percentage points (the stock lost 26.2% while the market gained 15.0%) | -41.2% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.3% of the share price. | -15.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $322.58 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -14.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $302.09 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -8.3% |
Price levels it has turned at before
SYK last closed at $276.97 on 2026-10-08. Since 2024-10-08 it has turned at 1 price below its last close and 11 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $267.85 | Support | 3.3% below the last close | turned there twice · 2026-09-11 to 2026-09-25 |
| $290.74 | Resistance | 5.0% above the last close | turned there twice · 2026-06-02 to 2026-09-16 |
| $306.97 | Resistance | 10.8% above the last close | turned there three times · 2026-07-02 to 2026-07-23 |
| $317.07 | Resistance | 14.5% above the last close | turned there three times · 2026-03-31 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $268.69.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.68 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$367.00 range $298.00 – $465.00; median $360.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SYK
- Consensus EPS estimate$3.57 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.0244 (-0.7%) from $3.59, on 2026-09-01, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Cybersecurity incidents affecting business operations","Macroeconomic risks including trade policy changes and tariffs","Market volatility and inflationary pressures impacting operational costs"]
What changed in the latest 10-Q
AI-assisted comparison of SYK's 10-Q filed 2026-05-11 against the prior one filed 2025-10-31.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-11) adds disclosure of a cybersecurity incident identified in Q1 2026 that caused business disruptions, with ongoing investigation
- Newer filing describes organizational restructuring in Q1 2026 creating new 'Ortho Tech' business combining orthopaedic instruments with Mako and enabling technologies
- Newer filing adds specific discussion of 2026 Supreme Court ruling in Learning Resources, Inc. v. Trump striking down certain tariffs and subsequent administration actions invoking Section 122 of Trade Act of 1974
- Newer filing adds discussion of potential tariff refunds for amounts paid in 2025 with uncertainty regarding availability, timing and amount
- Newer filing includes 'Ortho Tech' as a new reportable product line in Orthopaedics segment with Q1 2026 sales of $646M
- Removed:
- Older filing (2025-10-31) includes nine-month 2025 results and comparisons; newer filing (2026-05-11) reports only three-month 2026 results
- Older filing references 2024 Annual Report Form 10-K for risk factors; newer filing references 2025 Form 10-K
- Older filing includes 'Neuro Cranial' as separate product line in MedSurg and Neurotechnology segment; newer filing references 'Neuro Crani' (appears truncated) and reorganizes this content under new structure
- Older filing includes 'Recent Developments' section detailing Inari acquisition for $4,810M, credit facility changes, and debt issuances in February and June 2025; newer filing has no comparable transaction disclosures
- Reworded:
- Older filing describes Instruments as 'surgical equipment and navigation systems'; newer filing expands to include 'patient and caregiver safety technologies' and more detail on Instruments portfolio
- Newer filing provides expanded description of Medical segment to include 'clinical communication and artificial intelligence-assisted virtual care platform technology'
- Older filing states company 'segregate our operations'; newer filing states 'we will continue to have two business segments' reflecting new organizational structure
- Older filing references tariffs announced 'Beginning in 2025'; newer filing states 'In 2025' and adds developments occurring 'In 2026'
- Older filing macroeconomic section notes governments 'threatened or imposed reciprocal tariffs' and 'United States is in the process of negotiating'; newer filing provides more specific legal and regulatory updates
- Newer filing adds statement 'All historical financial segment information has been recast to conform to this new presentation' regarding organizational changes
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs Q3 2025) and compare different prior periods (Q1 2025 vs Q3 2024), limiting direct comparability of performance metrics
- Segment restructuring makes historical product-line comparisons difficult; Spinal Implants appears in newer filing with ($98.9)% change, suggesting reclassification or significant change from older filing structure
- Truncated text in newer filing at 'Neuro Crani' prevents complete assessment of organizational change description
Risk Factors
- Added:
- Detailed cybersecurity incident disclosure dated March 11, 2026, affecting corporate network with material financial impact in Q1 2026 (filed 2026-05-11)
- Reference to Form 8-K/A filing dated April 9, 2026 regarding material impact of cybersecurity incident on operations and financial results (filed 2026-05-11)
- Description of generative AI risks being used by malicious actors for targeted phishing and disinformation (filed 2026-05-11)
- Reference to increasing risk of civil unrest, political tensions, wars, or military conflicts such as U.S. combat operations in Iran affecting cybersecurity threat landscape (filed 2026-05-11)
- Disclosure of specific legacy third-party software components with layered security approach dependencies (filed 2026-05-11)
- Reference to Section 524B of the Federal Food, Drug, and Cosmetic Act compliance regarding security measures (filed 2026-05-11)
- Details on incident response protocols activation, engagement of external cybersecurity experts, regulatory notification, and customer/vendor communication (filed 2026-05-11)
- Description of remote work cybersecurity and cyber-liability risks affecting significant number of employees (filed 2026-05-11)
- Discussion of manual process workarounds potentially causing efficiency, sustainability, error, delay, and data integrity risks (filed 2026-05-11)
- Removed:
- Generic statement that company is not aware of any material changes to risk factors from Form 10-K for 2024 (filed 2025-10-31)
- Reworded:
- Generic reference updated from Form 10-K for 2024 to Form 10-K for 2025 (filed 2026-05-11)
- Notes:
- Older filing contains primarily boilerplate Risk Factors language with no specific incident disclosures; newer filing provides extensive specific details about March 11, 2026 cybersecurity incident
- Text of newer filing appears to be truncated/incomplete at end of provided excerpt
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 22 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 22 sells ($118M) — 3 selling insiders
- Last 180 days · read to 2026-10-040 buys · 36 sells ($219M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SYK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 23 matched disclosures for SYK from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding SYK as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 45,863,263
- Reported value $14,453,089,159
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SYK's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SYK had 7,671,881 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SYK had 2.00% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.2 days to cover at the same settlement.
- Reported short interest (shares) 7,671,881
- Short interest (% of shares outstanding) 2.00%
- Prior settlement (shares) 7,643,592
- Reported change 0.37%
- Days to cover (reported) 2.2
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Zimmer Biomet Holdings (ZBH)
- Medtronic (MDT)
- Johnson & Johnson MedTech (JNJ)
- CONMED (CNMD)
- Smith & Nephew
- STERIS (STE)
- Baxter International (BAX)
- Penumbra (PEN)
- Karl Storz
- Olympus Optical
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SYK vs…
Stryker Corporation is found in…
SYK shows up in…
Frequently asked questions
What does Stryker Corporation (SYK) do?
Stryker is a global medical technology company that provides innovative products and services in MedSurg, Neurotechnology, and Orthopaedics. Its portfolio includes surgical equipment, endoscopic systems, patient handling and emergency medical equipment, and robotic-arm assisted surgery technology used in joint replacements. The company serves healthcare facilities and physicians to improve patient outcomes through advanced surgical and clinical solutions.
What sector is Stryker Corporation (SYK) in?
Stryker Corporation (SYK) is classified in the Health Care sector. Its industry is Medical devices and equipment. It trades on NYSE.
Does SYK pay a dividend?
Yes — Stryker Corporation (SYK) pays a dividend, with an indicated yield of about 1.28% and 8-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-02). Informational only — not financial advice.
Who are Stryker Corporation's (SYK) competitors?
Notable peers of Stryker Corporation (SYK) include Zimmer Biomet Holdings, Medtronic, Johnson & Johnson MedTech, CONMED and Smith & Nephew. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in SYK?
Yes — we hold 23 matched STOCK Act disclosures for SYK from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Stryker Corporation (SYK) overbought or oversold right now?
Stryker Corporation (SYK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SYK come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.